Document:

Exhibit
10.34.1

 

Certain identified information
has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly
disclosed. [***] indicates that information has been redacted.

 

 

 

 

 

 

 

Exclusive International Distributor
Agreement

 

 

 

    	 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.

    

 

THIS EXCLUSIVE INTERNATIONAL DISTRIBUTION
AGREEMENT (the “Agreement”) is entered into as of October 5, 2015

between

		(1)	Curetis AG, Max-Eyth Strasse 42, 71088 Holzgerlingen, Germany

- hereinafter referred to as “Curetis”-

and

		(2)	Acumen Research Laboratories Pte Ltd, 10 Biopolis Road, #03-01, Singapore 138670

 

- hereinafter referred to as “Distributor”-.

The entities listed in no. (1) and (2)
above are also referred to as the “Parties”. This Agreement supersedes and replaces any and all previous distribution
agreements between the Parties.

RECITALS

		(A)	Curetis manufactures and sells molecular diagnostic products.

		(B)	Curetis wishes to appoint Distributor as the exclusive distributor of its molecular diagnostic
products initially in Singapore, Thailand, Indonesia and Malaysia and Distributor wishes to become the distributor for Curetis
on the terms and conditions set out in this Agreement.

		(C)	Both parties at a later point in time may mutally agree to amend the agreement to include further
territories of the ASEAN region.

    	2 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.

    

 

NOW IT IS AGREED as follows:

		1.	APPOINTMENT AND EXCLUSIVITY

		1.1	Curetis hereby appoints Distributor as its exclusive distributor for the products of Curetis described
in Attachment 1.1 (A) (hereinafter the “Products”) in the countries described in Attachment
1.1 (B) (hereinafter the “Territory”), subject to the provisions of this Agreement; Distributor
hereby accepts such appointment.

		1.2	Distributor shall purchase the Products exclusively from Curetis and resell them to third parties
in the Territory in his own name and on his own account, except as otherwise stated herein.

		1.3	Distributor shall not act as agent of Curetis, shall not represent Curetis in any way whatsoever
and shall have no authority whatsoever to enter into any obligations on behalf of Curetis, unless the Parties stipulate such right
in writing.

		1.4	Distributor shall not actively offer or sell, directly or indirectly, Products outside the Territory.
In particular Distributor shall not approach customers outside the Territory for instance by mail or e-mail, facsimile, visits,
through advertisements in media or other promotions specifically targeted at customers outside the Territory. Passive sales outside
the Territory shall, however, be permissible. Distributor shall neither establish branch offices nor keep any distribution warehouse
outside the Territory for the purpose of selling the Products. As far as member states of the European Economics Area (“EEA”)
are concerned, the restrictions under this Section 1.4 apply only to the extent that the active sales are prohibited in those territories,
to which Curetis has exclusively allocated other distributors or which it has reserved for itself. Curetis will inform Distributor
about such areas. As far as countries outside of the EEA are concerned all exports are prohibited, except for exports into other
ASEAN countries or such additional countries mutually agreed in writing between the parties.

		1.5	Distributor shall not order, be supplied with or distribute, directly or indirectly, the Products
or any products directly competing with the Products from any other party than Curetis during the entire term of this Agreement
as set forth in Section 21.1 below, however, not exceeding a maximum period of five (5) years following the conclusion of this
Agreement. For the purpose of this agreement, competing products shall mean instruments and consumables for cartridge-based sample
to answer molecular diagnostics tests that are directly competing with instruments and consumables that Curetis has introduced
into the market by the time of conclusion of this agreement, or publicly communicated to introduce into the market within three
years after the conclusion of this agreement.

		1.6	Curetis shall be entitled to sell the Products directly to the customers in the Territory listed
in Attachment 1.5 (hereinafter the “Direct Sales Customers”).

		1.7	In addition, Curetis may participate in all relevant fairs and exhibitions in the Territory in
order to promote the Products and Curetis’ trademark in cooperation

    	3 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.

    

with Distributor. In addition, Curetis
reserves the right to directly contact key opinion leaders in the Territory for the promotion of the Products and the Curetis trademark.

		1.8	Except as provided for in Section 1.6 above or in Section 1.9 below, Curetis will not, during the
term of this Agreement, distribute, actively promote or sell by itself the Products in the Territory, nor will it grant the right
to do so to any other person, firm, government or company. Except as provided for in Section 1.6 above or in Section 1.9 below,
Curetis will refer to Distributor all inquiries for the Products which are received from the Territory. Curetis may, however, without
liability to Distributor, enter into sales agreements for the Products outside the Territory, with persons, firms or corporations
having a place of business outside the Territory, provided that Curetis shall not knowingly enter into sales agreements or continue
with such agreements with persons, firms or corporations where the general sales or distribution of the Products is within or includes
the Territory.

		1.9	Curetis may terminate the exclusivity of the Distributor with two months’ prior written notice
to the end of a calendar month in case that the Agreement will effectively expire or terminate within no more than two (2) months.

		2.	GENERAL OBLIGATIONS OF DISTRIBUTOR

		2.1	The Distributor shall

		(a)	Devote sufficient financial resources and employ sufficient and well trained qualified marketing,
sales and technical personnel to effectively fulfill its obligations under this Agreement and to enable servicing activity of the
highest level. The professional standards of Distributor’s employees shall be, at all times, raised through education and
instruction. Qualification and training shall be documented and kept up to date.

		(b)	Provide on its own account adequate pre-sale and post-sale technical and scientific support services
in accordance with standards customary in the industry.

		(c)	Use commercially reasonable efforts to actively promote the sales of the Products, to create a
demand for the Products, in particular by (i) having its salesforce travelling, (ii) arranging displays,
(iii) participating in relevant trade fairs and exhibitions in the Territory at its own cost and expense- also upon reasonable
request of Curetis - and (iv) by other methods at its command. It shall advertise the Products and act for Curetis in a manner
fitting its position as exclusive distributor, all in accordance to the Local Marketing Plans (as defined in Section 4.2 below).

		(d)	Act in furtherance of the best interest of Curetis and at no time do, cause or permit to be done,
published or said, any information, act, or thing from whatever source, which is or may be detrimental to the best interest and/or
business reputation of Curetis.

    	4 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.

    

		(e)	Submit market analysis and Local Marketing Plans (as defined in Section 4.2 below) to Curetis (including
without limitation: expenses, workshops, conferences, mailings and advertising).

		(f)	Notify Curetis immediately whenever there are actions or changes in the market in the Territory
which affect, or might affect, Product sales (such as new competitors, new regulations, changes in reimbursement policies, etc).

		(g)	Market and sell the Products under Curetis’ logo, trademark and label in their original package
or in case that the original package does not comply with the applicable regulatory requirements in a modified original package
as mutually agreed with Curetis. Distributor shall ensure that labeling and packaging is in compliance with the applicable laws
and regulations and that the modifications to the package are limited to those required under the applicable laws and regulations.

		(h)	Inform the designated Curetis representative set forth in Section 24 below immediately about any
hazards and/or events or any potential hazards and/or events whatsoever occurring in course of the use of the Products.

		(i)	Distributor shall not print any sales brochures or other promotional material for the Products
that do not show Curetis’ logo, trademark and label. Any sales brochures and other promotional material used by Distributor
under this Agreement shall include the following wording: “[Name of Distributor], exclusive distributor of [Curetis’
Product] in [Territory].”

		(j)	Upon prior consultation and cooperation with and approval by Curetis, obtain approval from the
competent health, medical device and other relevant authorities for import and distribution of the Products, if necessary, and
comply with all applicable laws and regulations. Distributor shall promptly notify Curetis about any communications with such authorities.
Distributor shall inform Curetis about any form of non-compliance with such laws and regulations.

		(k)	Promptly take all necessary and required acts and measures to obtain — upon prior consultation
and cooperation with and approval by Curetis - regulatory marketing approval for those countries in the Territory for which the
CE-marking obtained by Curetis for the Products is inapplicable or insufficient for the marketing, sale and distribution of the
Products in such country. Distributor shall promptly notify Curetis about any communications with such authorities. Any clinical
trials which Distributor intends to conduct or have conducted for obtaining regulatory marketing approval for a country in the
Territory or for any other regulatory approvals require the prior written consent of Curetis. Distributor shall constantly keep
Curetis informed about such clinical trials and provide Curetis with all data, documents and information in connection there with
including the results.

		(l)	Distributor shall inform Curetis about all infringements of proprietary rights of Curetis that
come to Distributor’s knowledge. Distributor shall use its

    	5 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.

    

commercially reasonable efforts
to support Curetis against such infringement of rights.

		(m)	Distributor shall observe all applicable laws and regulations, particularly those affecting the
marketability of the Products as such as well as those relating to the import, sale, distribution and marketing of the Products
and inform Curetis about any changes hindering or impeding the sale of the Products in the Territory.

		(n)	Seek Curetis written approval about local advertising and promotional materials produced by or
on behalf of Distributor prior to its publication; such approval not releasing Distributor from its sole responsibility of compliance
of such material with all applicable laws and regulations. Any advertising and promotional materials must correspond and comply
with the sample materials provided by Curetis under Section 3.5 below. Translations of advertising and promotional materials including
instructions for use are the sole responsibility of Distributor and must be rendered at Distributor’s costs in a professional
manner by a certified translator and in compliance with all applicable laws and regulations, in particular any regulatory requirements.
Statements in advertising and promotional materials of Curetis may in no event be altered by Distributor. Labels may in no event
be changed or obliterated by Distributor. Distributor shall adhere to the CE-marking, unless required differently in the Territory.
Any revisions to the advertising and promotional materials by Curetis, including the instructions for use, must be translated by
the Distributor without undue delay, inserted in the local advertising and promotional materials, including the instructions for
use, and promptly provided by Distributor to customers and potential customers in the performance of its obligations hereunder.
Customers of Distributor shall be informed about significant changes to the advertising and promotional
materials or the instructions for use by Distributor in accordance with the applicable laws and regulations.

		(o)	Distributor shall not involve a third party subcontractor for the performance of its obligations
under this Agreement unless with the prior written consent of Curetis. Curetis shall not unreasonably withhold such consent.

		3.	GENERAL OBLIGATIONS OF CURETIS

		3.1	Curetis shall, upon Distributor’s request, provide support services, including technical
and scientific training, to Distributor’s personnel for the promotion, marketing and distribution of the Products as well
as the provision of technical services by Distributor under this Agreement (hereinafter the “Training”).

		3.2	As part of the Training, Curetis shall offer an introductory training session to staff members
of Distributor free of charge (hereinafter “Introductory Session”). The Introductory Session shall take place
at the business seat of Curetis in Holzgerlingen, Germany or such other location as may be mutually agreed between the Parties
to this Agreement. The travel costs and out-of-pocket expenses of Distributor’s personnel participating in such Introductory
Session shall be borne by Distributor.

    	6 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.

    

		3.3	Any further Training beyond the Introductory Session shall be conducted by Curetis upon mutual
agreement between the Parties.

		3.4	Curetis shall support and cooperate with Distributor in his efforts to obtain regulatory marketing
approval in those countries in the Territory for which the CE-marking is inapplicable or insufficient for the marketing, sale and
distribution of the Products in such country in the Territory, including providing analytical and clinical validation data used
in CE mark registration. Distributor hereby guarantees that Distributor shall strictly adhere to the instructions for use of the
Product and all other information and data provided by Curetis in connection with the Products and to refrain from any misrepresentations
vis-à-vis customers and/or competent regulatory authorities in connection with the Products, Curetis and/or this Agreement.

		3.5	Curetis shall support Distributor in its sales and marketing activities. Curetis shall provide
Distributor with samples of advertising and other promotional material (e.g. catalogues, prospectuses etc.) in the German and/or
English language free of charge. This promotional material will remain Curetis’ property and shall be used by Distributor
for the production of local advertising and promotional materials as set forth in Section 2.1(n) above. Curetis shall have the
right to amend its advertising and other promotional material with reasonable advance written notice to Distributor in case of
modifications, alterations, or improvements of any or all of the Products, or ingredients of Products, in case of a discontinuation
of the manufacturing of all or specific Products or ingredients of Products or on other reasonable grounds.

		3.6	Curetis hereby grants to Distributor for the duration of the Agreement the nonexclusive license
to use Curetis’ trademark, logos and other markings used by Curetis, as listed in detail in Attachment 3.6 hereto,
in order to promote the sale of Products within the scope of Section 2.1(g) above. The grant of such license shall be free of charge
and shall be limited in scope in accordance with the terms of this Agreement.

		4.	MARKETING STRATEGY

		4.1	Curetis is solely responsible for the overall marketing strategy and positioning of the Products
worldwide and in particular in the European Union (hereinafter the “Overall Marketing Strategy”). Curetis shall
inform Distributor in reasonable detail about the Overall Marketing Strategy and any changes to it.

		4.2	Distributor shall be responsible for the local marketing in the Territory which will be agreed
upon by the Parties (hereinafter the “Local Marketing Plan”). The Local Marketing Plan shall be based on and
correspond with the Overall Marketing Strategy. The marketing activities of Distributor under the Local Marketing Plan shall include
hospital marketing as well as physician and microbiology and / or core laboratory marketing as described in detail in the Local
Marketing Plan.

    	7 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.

    

		4.3	Distributor acknowledges that Curetis has the greatest interest in displaying a uniform Overall
Marketing Strategy and Local Marketing Plan to potential customers throughout the world. Therefore Distributor agrees to participate,
on a best effort basis, in the Overall Marketing Strategy, along with other distributors, and to implement the Local Marketing
Plan in the Territory.

		4.4	In order to adjust the Local Marketing Plan to modifications in the Overall Marketing Strategy
as well as the specific market needs in the Territory, the Parties agree to meet at regular intervals, which will be defined in
good faith between the parties, with or without other distributors of the Products at the head office of Curetis in Holzgerlingen,
Germany or any other place as may be mutually agreed between the Parties (hereinafter “Marketing Meeting”) and
to discuss the Local Marketing Plan in its then current version as well as any issues in connection therewith. Curetis shall schedule
the Marketing Meeting with reasonable advance notice. Each Party shall participate in such Marketing Meeting with the relevant
marketing representatives. Any travel and out-of-pocket expenses shall be borne by the Party that incurred such costs.

		4.5	Distributor shall implement, at its own cost, unless expressly agreed otherwise by the Parties,
the Overall Marketing Strategy and the Local Marketing Plan by using various devices of Curetis such as logos, trademarks, markings,
labels, signs, CDs, DVDs, and any other media provided by the same.

		4.6	It is expressly agreed that the marketing concepts developed by Curetis remain its sole property
and shall, in no way, be used by Distributor in connection with promotion of other goods than the Products.

		4.7	If Distributor shall fail to perform his duties relating to uniform performance of the Overall
Marketing Strategy and the Local Marketing Plan, this shall be deemed a breach of an essential obligation as set forth in Section
21.3 below.

		5.	RECORD KEEPING / REPORTING

		5.1	During the term of the Agreement, Distributor shall keep true, accurate and complete records of
the data collected in connection with the acquisition, promotion, advertising, sale, stocks, storage, distribution, delivery, services
and other activities relating to the Products. These records shall specifically ensure the traceability of the individual Products,
lots and batches for recall campaigns as set forth in Section 12 below or required by the relevant regulatory authorities. Distributor
shall also keep true, accurate and complete records of the data collected in connection with obtaining the required regulatory
approvals in the Territory including the documentation of clinical trials, as applicable. The records shall be furnished to Curetis
upon request. Additionally, each party shall retain such records as are required by the applicable laws and regulations and at
least for a period that is necessary for the administration of the Agreement, but in no case for a period of less than ten (10)
years from the date such records were generated and not less than

    	8 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.

    

five (5) years after the expiration
or termination of this Agreement, whichever is later.

		5.2	Within thirty (30) days after the end of each calendar quarter during the term of this Agreement,
Distributor shall provide to Curetis a written quarterly report which shall contain true, accurate and complete information about
such calendar quarter on a country-by-country and product-by-product basis:

		(a)	Sales results, including the invoiced and the received amounts for sales of Products to end users
as well as to other dealers;

		(b)	List prices;

		(c)	Deductions for returns (including withdrawals and recalls);

		(d)	Sales rebates (i.e. price reductions) and overall average rebates;

		(e)	Volume (i.e. quantity) discounts;

		(f)	Sales taxes and other taxes directly linked to the sales of the countries concerned;

		(g)	Information whether any sales support from Curetis is required.

The report shall include the above
information for combined Products in the form of in-vitro-diagnostic kits as well as for each individual component of such combined
Products, provided these components may be sold separately.

		5.3	Distributor shall allow Curetis audit access for the inspection of the abovementioned records including
its business records and financial statements. Curetis shall give Distributor at least ten (10) days written notice of any planned
audit, unless Curetis has reasonable grounds to suspect fraudulent activity or other impropriety by Distributor, its permitted
subcontractor or any third party in connection with this Agreement. Distributor shall and shall ensure that such information, assistance
and access to the premises are afforded as may be necessary for Curetis to fully and promptly carry out such audit. This section
shall survive the expiration or termination of the Agreement for a period of five (5) years thereafter.

		6.	FORECAST AND MINIMUM PURCHASE

		6.1	Upon the execution of this Agreement, Distributor shall provide to Curetis on a quarterly basis
a detailed rolling forecast on the expected figures of the deliveries of the Products for the following twelve (12) months. Such
forecasts shall be submitted to Curetis no later than 15 February, 15 May, 15 August and 15 November and shall provide the forecasts
for the respective four (4) following calendar quarters. Only the forecast for each respective first quarter of a rolling forecast
is considered binding - the forecasts for the remaining 9 months shall not be binding on either Party and shall be used for planning
purposes only.

    	9 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.

    

		6.2	Irrespective of the forecast pursuant to Sections 6.1 above, Distributor shall be obligated to
purchase at least the minimum amounts of the Products per contractual year specified in Attachment 6.2 (hereinafter the “Minimum
Purchase”). The order date shall be decisive for the allocation to a contractual year. In the event that Distributor does
not fulfil the Minimum Purchase in a contractual year, Curetis may elect to (i) terminate the Agreement with three months’
prior written notice to the end of a month informing the Distributor about its failure to fulfill the Minimum Purchase, (ii) terminate
the exclusivity of the Distributor in the Territory on three months’ prior written notice to the end of a month for all Products,
or (iii) terminate the exclusivity of the Distributor in the Territory on three months’ prior written notice to the end of
a month only for the Product for which the Minimum Purchase was not achieved, provided in these cases that Distributor does not
cure its failure to fufill its Minimum Purchase obligations for the respective contractual year during such notice periods. The
right to terminate the Agreement or the exclusivity of the Distributor pursuant to the previous sentence shall not release Distributor
from his Minimum Purchase obligations for the respective contractual year. The right to terminate the Agreement or the exclusivity
of the Distributor pursuant to this Section 6.2 sentence 2 above shall expire after the first three months following the contractual
year in which Distributor failed to fulfill the Minimum Purchase. A waiver of the aforementioned right to terminate the Agreement
or the exclusivity of the Distributor for a contractual year, whether by conduct or otherwise, shall not be deemed to be or construed
as a further or continuing waiver of such rights under this Agreement regarding the following contractual years.

		6.3	In case the exclusivity of the Distributor is terminated pursuant to Section 6.2 above for one
or for all Products, the Minimum Purchase shall be adjusted jointly and based on mutual agreement by Curetis and Distributor in
good faith.

		6.4	In case of a permitted modification, alteration, or improvement of any or all of the Products,
or ingredients of Products which may influence the agreed Minimum Purchase, or a discontinuation of the manufacturing of specific
Products or ingredients of Products, the Minimum Purchase shall be adjusted jointly and based on mutual agreement by Curetis and
Distributor in good faith in proportion to such change.

		6.5	No later than ninety (90) days prior to the beginning of a renewal of the term of this Agreement
pursuant to Section 21.1 below, the Parties shall agree on the Minimum Purchase for the years following the initial three-year
term, taking into account the actual value of sales achieved in the respective previous year. In case that the Parties do not reach
an Agreement within the period of time set for in sentence 1 above, this Agreement shall automatically terminate at the end of
the initial or any renewal term.

    	10 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.

    

		7.	PRICES

		7.1	The prices at which Distributor shall buy and Curetis shall sell the Products bought and sold hereunder
shall be as per Attachment 7.1 (hereinafter referred to as the “Prices”).

		7.2	Curetis shall have the right at any time to adjust its Prices, at maximum three (3) times of the
inflation rate of the previous year in the Territory, by giving the Distributor written notice to that effect not less than four
(4) months prior to the date upon which the adjusted Prices are to become effective, provided that Curetis can reasonably demonstrate
that such price adjustment is based on increased material or manufacturing costs of Curetis or its subcontractors.

		7.3	The Prices are to be understood “net, EX WORKS (Curetis AG, Germany), or address of any other
Curetis contractor)” in accordance with Incoterms 2010.

		7.4	Distributor shall not be bound in any way whatsoever by the prices paid to Curetis, but shall determine
at his own risk the prices for the sale of Products to third parties. However, Distributor has to take care that Products remain
competitive within the Territory. Distributor agrees to inform Curetis of significant alterations to the resale prices in due time
before they enter into force. Upon the entering into force of this Agreement, Distributor agrees to inform Curetis of the prices
at which it intends to commence sale of the Products as detailed in Attachment 7.4 hereto.

		8.	ORDERS AND DELIVERY

		8.1	Curetis sells the Products to Distributor on the basis of its Standard Terms of Delivery and Sale
attached hereto as Attachment 8.1 or in the version applicable at that time during the term of the Agreement. The
Standard Terms of Delivery and Sale may be adjusted by Curetis upon reasonable advance written notice to Distributor, provided
that (i) there are material grounds for such amendment and (ii) such material grounds as well as the extent of such amendment are
disclosed to Distributor in the written notice thereof. The new terms shall only be applicable for all new orders made after the
amendments. In case of inconsistencies between this Agreement and the applicable Standard Terms of Delivery and Sale the provisions
of this Agreement shall prevail.

		8.2	Distributor shall make its orders by regular mail, facsimile, and/or e-mail to Curetis’ distribution
site(s) in Germany. Curetis shall confirm receipt of an order of Distributor within two (2) weeks by regular mail, facsimile, or
e-mail and state acceptance of the order together with the planned delivery date or, if applicable identify any problems or objections.
Each and every purchase order shall become binding upon Curetis with Distributor’s receipt of Curetis’ acceptance of
the order.

		8.3	The estimated delivery time for an order shall be thirty (30) days upon Distributor’s receipt
of Curetis’ acceptance of the order for disposables and 8 weeks for instruments. The compliance by Curetis with any agreed
delivery dates is subject to Curetis’ proper and timely receipt of supplies from its vendors. Curetis shall

    	11 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.

    

inform Distributor promptly about
such delays, including a notification about the reasonably adjusted estimated delivery times. Any agreed delivery dates shall not
be considered as absolute unless expressly stated otherwise.

		8.4	Delivery of Products purchased by Distributor hereunder shall be made for and on behalf of Distributor,
EX WORKS (Incoterms 2010), Curetis AG, Germany or address of any other Curetis contractor in Germany. Curetis or its contractor
as stated above will package all products suitable for shipment.

		8.5	Curetis is released from the obligation to deliver the Products for any period in which it is prevented
from delivery owing to strike, riots, civil commotions, force majeure or other circumstances for which it is not responsible. In
this event, Curetis shall have the right to allocate pro rata portions of those Products available to its various distributors
worldwide. This shall also apply in case of delay of supply from Curetis’ subcontractors.

		8.6	Curetis may withhold shipment of Products because of the outstanding balance of Distributor’s
account or if it determines that Distributor is not financially reliable. In this case Curetis may also make it a condition of
further deliveries that the Distributor provides reasonable security or Curetis may demand payment in advance. If the foregoing
conditions regarding Distributor’s ability to pay or creditworthiness are not rectified to Curetis’ reasonable satisfaction,
this will constitute an essential breach of this Agreement and Curetis may terminate this Agreement pursuant to Section 21.3. Distributor
shall not be permitted to take any credit against amounts owed to Curetis without prior written authorization by Curetis.

		8.7	The Products remain the property of Curetis until all outstanding payments for all affected deliveries
have been received by Curetis. Distributor, however, shall be entitled to sell the Products in accordance with proper business
practice to third parties. For reasons of security, Distributor agrees to assign any outstanding claims against said third parties
resulting from these sales to Curetis, until full payment on any unsettled debts has been effected to Curetis. Curetis agrees to
this assignment. The assignment shall not exceed 100% of the unsettled debts. Distributor shall be authorized to collect these
claims assigned to Curetis in its own name and on its own account as long as this authorization is not revoked by Curetis. Curetis
shall not revoke the authorization as long as the Distributor fully satisfies its payment obligations and does not breach its obligations
under this Agreement. In case that Distributor is in default with any of its payment obligations under this Agreement or breaches
any terms and conditions of this Agreement, Distributor shall upon request of Curetis promptly report to Curetis the assigned claims
and the respective debtors and furnish Curetis with all documents and information required for asserting the claims. In case the
Products are pledged by third parties or in case of equivalent acts, Distributor shall advise about the ownership of Curetis and
promptly inform Curetis in written form to enable Curetis to protect their right, title and interest. Distributor shall take all
necessary and required steps to ensure that the extended retention of title for all outstanding payments
for all affected deliveries

    	12 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.

    

of Curetis in the form described
in this Section 8.7 above is effective under the applicable laws in the Territory. In case that an extended retention of title
in the form described in this Section 8.7 above is not permissible under the applicable laws in the Territory, Distributor shall
ensure that Curetis is granted a security which comes as close as possible to the purpose of a retention of title as intended by
the Parties.

		9.	PAYMENTS

Invoices are due for payment sixty
(60) days from the date of the invoice. Payments shall be made in cash by wire transfer in immediately available funds to the German
bank account determined by Curetis without any deductions. Payments shall be made in Euro. Charges by Curetis’ banks are
to be paid by Curetis. All other charges are to be paid by Distributor.

		10.	TAXES

The term “Prices”
as used in this Agreement, shall exclude any taxes, import duties, use or privilege taxes, or excise or similar taxes or duties
levied by any country in the Territory upon Curetis or the Products, as the result of any manufacture, sale, delivery or use of
any unit sold hereunder. Distributor shall be responsible for the payment of any such taxes or duties which may be so levied by
countries within Distributor Territory.

		11.	INVENTORY

		11.1	It is the responsibility of the Distributor to have a balanced inventory sufficient to avoid any
customer back order as to avoid any Product loss due to the Product stability. Distributor thus agrees, at its cost, to carry a
minimum representative stock of Products sufficient to meet the requirements for the Territory, which shall be at least 20% of
the applicable Minimum Purchase. The inventory shall be kept in storage under the mandatory storage conditions set forth in Attachment
11.1 which must be complied with by Distributor at all times.

		11.2	Distributor shall allow Curetis audit access for quality and regulatory inspections including the
inspection of the storage conditions at the respective place of storage of Distributor, its permitted subcontractor or any other
third party once every year, unless Curetis has reasonable grounds to suspect fraudulent activity or other impropriety by Distributor,
its permitted subcontractor or any third party in connection with this Agreement or in case of other legitimate reasons of Curetis
(hereinafter “Ad Hoc Audit”). The audits under this Section shall include the inspection of any records, data
and documents that Curetis deems relevant in connection with its quality and regulatory inspections.
Curetis shall give Distributor at least ten (10) days written notice of any planned audit, unless in case of an Ad Hoc Audit where
no notice period is required. Distributor shall and shall ensure that such information, assistance and access to the premises,
records, data and documents are afforded as may be necessary for Curetis to fully and promptly carry out any audit. The same shall
apply in case that a competent regulatory authority

    	13 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.

    

conducts an audit at the Distributor’s,
its permitted subcontractor’s or at a third party’s site in connection with the Products or this Agreement. This Section
11.2 shall survive the expiration or termination of the Agreement for a period of five (5) years thereafter.

		12.	RECALLS, ADVERSE EVENTS,
COMPLAINTS

		12.1	The Parties shall notify each other of the following incidents without undue delay:

		(a)	Any adverse events of which the Parties become aware in relation to the Products or any similar
or equivalent products worldwide;

		(b)	Any defect in the quality of any Product delivered by Curetis under this Agreement or if Distributor
establishes deficiencies in the Product documentation provided by Curetis including packaging, labeling and instructions for use
or promotional and marketing material;

		(c)	Any defects or deficiencies of the Products which appear during the storage and/or further processing
and/or after marketing of the Products in the Territory;

		(d)	Any complaints of which Distributor becomes aware in relation to the Products or any similar or
equivalent products in the Territory. Complaints will be reported in a mutually agreed format and manner.

		12.2	Curetis shall be responsible for the technical clarification and internal investigation of complaints
in respect of the Products. Distributor agrees to make all commercially reasonable efforts to support Curetis in order to clarify
and resolve the source for the adverse event, defect, deficiency or complaint. In particular, Distributor shall promptly upon request
of Curetis provide to Curetis any information and records on the Products in questions in accordance with Section 5 above, especially,
any information required by Curetis to fulfill its reporting and documenting obligations to the competent regulatory authorities
pursuant to Section 12.4 below.

		12.3	Curetis shall in its own discretion decide whether to put Products or entire batches or lots of
Products on quality hold due to reported adverse events, defects, deficiencies or complaints and whether a product recall campaign
shall be initiated. Curetis shall inform Distributor without undue delay prior to implementing any recall campaigns or quality
holds. Distributor shall fully cooperate with Curetis in case a recall campaign is initiated. In case Curetis requests a quality
hold of Product lots or batches of Products, Distributor shall immediately upon notification refrain from selling, distributing
and marketing the respective lot or charge. In case that Curetis requests a Product recall, Distributor shall immediately upon
notification identify any Product deemed to be affected by such recall including Products already delivered to customers and strictly
follow Curetis’ instructions. Curetis shall reimburse Distributor for any reasonable costs incurred by Distributor’s
activities performed in connection with a recall campaign or quality hold provided

    	14 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.

    

that the reason for the recall does
not fall in the responsibility of Distributor. All other claims shall remain unaffected.

		12.4	In case of any adverse events, defects, deficiencies or complaints as well as recall campaigns
Curetis shall comply with all reporting obligations to the German competent regulatory authorities as well as those in the Territory
under the applicable laws and regulations. Upon request of Curetis, Distributor shall be responsible for any such reporting obligations
described in the previous sentence to the competent national regulatory authorities in the Territory in compliance with the applicable
laws and regulations, provided such reporting by Distributor is legally permissible. In case that Curetis as the legal manufacturer
is mandatorily required to report to such national regulatory authorities, Distributor shall immediately notify Curetis in writing
thereof and shall take all commercially reasonable and required steps to assist Curetis in complying with such reporting obligations.

		12.5	In the event of any claim, suit or action arising out of any defects or deficiencies of the Products
or the advertising or promotional material, in particular under product liability law, Distributor shall promptly notify Curetis
in writing. Any such claim, suit or action shall be defended at Curetis’ costs and risks provided that the claims, suits
or actions are not based on an act exerted by Distributor. In case that Curetis shall bear the costs the aforesaid claim, suit
or action shall be defended taking into consideration that the good will vis-à-vis customers of Distributor shall not be
jeopardized.

		12.6	The obligations of Distributor under this Section 12 shall survive the expiration or termination
of this Agreement.

		13.	GUARANTEES OF DISTRIBUTOR

		13.1	Distributor shall be solely responsible to its customers for any and all guarantees which it makes
relating to Products.

		13.2	Distributor guarantees that, in performing work for Curetis under this Agreement, it will not be
using any trade secrets or confidential information of any company which may be considered to constitute a competitor of Curetis
and:

		(a)	with which Distributor may have been previously associated as a distributor for the products of
such company, or

		(b)	with which Distributor may now be associated as a distributor for the products of such company,
or

		(c)	with which Distributor may hereafter be associated as a distributor for the products of such company
during the term of this Agreement.

    	15 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.

    

		14.	DEFECTS

		14.1	Distributor shall inspect the Products promptly without undue delay upon delivery thereof at Distributor’s
premises. If any faults and defects arising as a result of faulty workmanship or defective material or short or wrong deliveries
are detected during the inspection (hereinafter “Apparent Defects”), Distributor shall notify Curetis by regular
mail or facsimile promptly without undue delay after receipt of the Products. In the event of latent defects present at the time
of the passing of the risk, but not capable of being discovered by Distributor upon such an inspection (hereinafter “Concealed
Defects”) Distributor shall inform Curetis by regular mail or facsimile promptly without undue delay after the discovery
of such Concealed Defects. The notification by Distributor of Apparent Defects and Concealed Defects shall include sufficient information
for Curetis to identify the concerned production lot and batch. If Distributor fails to notify Curetis within the timelines set
forth in this Section 14.1, the Products shall be deemed to have been accepted without reserve; § 377 German Commercial Code
shall apply accordingly.

		14.2	Rejected Products pursuant to Section 14.1 above must be returned to the departure place indicated
by Curetis using the carrier appointed by Curetis. Curetis will bear the costs of such returns. Each package must be labelled with
the return number to be provided by Curetis and to be affixed to such package by the carrier of Curetis.

		14.3	If Curetis has been notified of a defect in a timely and proper manner pursuant to Section 14.1
above, Curetis may, at its own discretion, choose to either repair the Product or ingredient thereof or supply a replacement ingredient
or replace the entire Product within a reasonable period of time. Any costs and expenses incurred in connection with the repair
or replacement including transportation costs, labor costs and material costs shall be borne by Curetis.

		14.4	In the event that the defect cannot be eliminated within a reasonable amount of time by Curetis
or in case that the repair or replacement is deemed to have failed for other reasons, Distributor may, at its sole discretion,
rescind from the order or claim damages or reimbursement of frustrated expenses Claims for damages or reimbursement of frustrated
expenses are subject to Section 16 below. The rescission from an order shall not exclude any right to damages.

		14.5	The repair or replacement shall only deemed to have failed in case that (i) Curetis was granted
sufficient time and opportunity for such repair or replacement without achieving the desired result, whereby the unsuccessful second
attempt shall be deemed a failure, unless the nature of the Product or the defect or other circumstances require differently, (ii)
in case that the repair or replacement is deemed impossible, (iii) in case that Curetis refuses or unreasonably delays the repair
or replacement, (iv) in case that there are reasonable doubts that the repair or replacement may be successful or (v) in case that
such actions are unacceptable to the Distributor and unreasonable for other reasons.

    	16 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.

    

		14.6	Claims for product defects shall become time-barred twenty-four (24) months after the Distributor
received the instrument systems and shall become time-barred, in case of properly stored consumables, within the consumables’
expiration period or within six (6) months after the Distributor received said consumables, whichever comes earlier. This limitation
shall not apply in case of a liability of Curetis due to intentional misconduct or gross negligence by Curetis, its legal representatives
or its vicarious agents and in the case of culpable injury to life, body and health by Curetis, its legal representatives or vicarious
agents.

		15.	SHELF-LIFE GUARANTEE

		15.1	Due to the shelf-life of the Products, Curetis hereby grants the following shelf-life guarantee
as set forth in this Section 15, which shall be timely limited to a period of six (6) months following the date of production (hereinafter
the “Warranty Period”), provided, however, that the Products and their ingredients are used and handled in accordance
with this Agreement and stored by Distributor under the storage conditions specified in Attachment 11.1.

		15.2	In the event that Distributor can demonstrate by competent evidence that during the Warranty Period
a Product or any ingredient of a Product is or has become defective in material under normal handling, uses and storage as specified
in Attachment 11.1, the defect shall be deemed present at the time of the passing of the risk so that Sections 14 and 16 shall
apply accordingly. This shelf-life guarantee shall, however, in no event trigger any strict liability regardless of fault.

		15.3	Curetis shall be released from all obligations under its shelf-life guarantee set forth in this
Section 15 in the event that Products or their ingredients have been subjected to misuse, neglect or accident.

		15.4	Except for the shelf-life guarantee under this Section 15, there are no further guarantees of Curetis
under this Agreement, whether expressed or implied, including, but not limited to, warranties of merchantability and fitness for
a particular purpose other than the ordinary purposes for which the Products are used, guarantees regarding the validity of underlying
intellectual property rights, know how and other rights of Curetis and guarantees of non-infringement of intellectual property
or other third party rights.

		16.	LIABILITY

		16.1	Any claims for damages or reimbursement of frustrated expenses are subject to the following restrictions
regardless of their legal basis:

		16.2	The Parties shall be fully liable in the event of intentional misconduct or gross negligence by
the respective Party itself, its legal representatives or its vicarious agents. In addition, each Party shall be fully liable (i)
in the case of noncompliance with guarantees, except as set forth in Section 15 above, (ii) in the case of culpable injury to life,
body and health of such Party, its legal representatives or vicarious

    	17 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.

    

agents and (iii) in case of a statutory
liability under the German Product Liability Act.

		16.3	In the case of a culpable violation of essential contractual obligations, meaning principal obligations
enabling the proper execution of the contract and upon which the other Party therefore relies and may rely, the Party shall be
liable on the merits. The liability shall in this case, however, be limited to the contractually typical damage that can be reasonably
foreseen.

		16.4	In all other cases, any claims for direct or indirect damages (on any legal basis whatsoever) including
any compensation claims based on breach of any pre-contractual duty, or tortuous claims) shall be excluded.

		17.	MODIFICATION OF PRODUCTS

		17.1	Curetis shall have the right to modify, alter, or improve any or all of the Products, or ingredients
of Products, and shall have the right to discontinue the manufacturing of all or specific Products or ingredients of Products upon
not less than ninety (90) days prior written notice to Distributor, provided such modification, alteration or improvement is in
compliance with the applicable laws and regulations including the marketing authorization. Curetis will make available to Distributor
documentation describing any such modification, alteration, or Product improvement. Curetis’
rights to modify, alter, or improve any or all of the Products, or ingredients of Products, and to discontinue the manufacturing
of all or specific Products or ingredients of Products shall not apply to firm orders accepted by Curetis.

		17.2	Distributor shall not make any modifications, alterations, or improvements in any of the Products
without prior written consent of Curetis. In case of discontinuance of a Product, the Distributor shall have the right to distribute
another product which would better fit his market needs.

		17.3	Distributor shall not change or modify the brand or the basic design or appearance of the Products.
Distributor shall not, without the prior written consent of Curetis, make any change or modification whatsoever of the Products,
in particular no changes that could adversely affect the Product’s quality, performance or conformity to applicable legal
requirements or regulatory approvals of the Products, or that could adversely affect the marketability of the Products.

		17.4	The Products shall, at all times, be marketed or displayed in their original packaging and using
Curetis’ trademarks, logos, labels, designs and marketing devices, as may be then applicable. Distributor agrees not to alter
packaging, trademarks, logos, labels, designs and marketing devices without the prior written consent of Curetis.

		18.	PARTY RELATIONSHIP

		18.1	This Agreement does not create an employer-employee relationship between Curetis and Distributor,
nor any agency, joint venture or partnership. Distributor

    	18 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.

    

shall have no authority to act for
or to bind Curetis in any way, to alter any of the terms or conditions of the standard forms of Curetis, to warrant or to execute
agreements on behalf of Curetis, or to represent that Curetis is in any way responsible for the acts or omissions of Distributor.
Distributor shall be an independent contractor only.

		18.2	Distributor agrees to hold Curetis harmless from violation of the conditions contained in this
Section 18.

		19.	CONFIDENTIAL INFORMATION

		19.1	Beginning with the signing of this Agreement and during the term of the Agreement and any time
thereafter, all information disclosed by one Party to the other Party hereunder shall be maintained in confidence by the receiving
Party and shall not be disclosed to a third party or used for any purpose other than the purpose contemplated under this Agreement
without the prior written consent of the disclosing Party, provided that disclosure may be made of any of the information as necessary
to obtain marketing authorizations and to market the Products to the purchasers and except to the extent that the disclosing Party
can prove by competent evidence that such information received from the disclosing Party:

		(a)	is known by the receiving Party at the time of its receipt, and not through a prior disclosure
by the disclosing Party, as documented by business records;

		(b)	is properly in the public domain, or enters into the public domain after its disclosure to the
receiving Party through no fault of the receiving Party;

		(c)	is subsequently disclosed without any confidential obligation to a receiving Party by a third party
who may lawfully do so and is not under an obligation of confidentiality to the disclosing Party;

		(d)	is developed by the receiving Party independently of the Information received from the disclosing
Party.

		19.2	The receiving Party may disclose confidential information, without violating its obligations under
this Section 19, to the extent the disclosure is required by applicable law or by a valid order of a court or other governmental
body having jurisdiction, provided that the receiving Party gives reasonable prior written notice to the disclosing Party of such
required disclosure and, at the disclosing Party’s request and expense, cooperates with the disclosing Party’s efforts
to obtain a protective order preventing or limiting the disclosure, requiring that the confidential information so disclosed be
used only for the purposes for which the law or order requires, and/or to obtain other confidential treatment of the confidential
information so disclosed.

		19.3	In particular, Distributor will hold in confidence the contents of this Agreement and all information
designated as confidential by Curetis relating to Products sold

    	19 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.

    

hereunder or its underlying intellectual
property and know how not a matter of public record.

		19.4	Distributor shall ensure that its employees and other personnel refrain from disclosing any of
Curetis’ information to any person outside Distributor’s organization by submitting to obligations of confidentiality
not less stringent than those contemplated in this Agreement. Release of such confidential information by Distributor shall be
subject to prior written approval by Curetis.

		19.5	The provisions of this Section shall remain in full force and effect for 10 (ten) years following
the expiration or termination of this Agreement.

		20.	INTELLECTUAL PROPERTY

		20.1	Curetis is owner of trademarks, patents, registration rights and know-how used for Products. Unless
stated otherwise in Section 3.6 above, utilization of these intellectual property rights by Distributor shall be regulated by a
separate license agreement.

		20.2	Distributor recognizes the validity of the aforementioned title to any and all trademarks and/or
trade names that may be or may have been in use by Curetis in any country, in respect of the Products, whether or not the same
shall have been registered.

		20.3	Distributor shall neither inside nor outside the Territory take any action in respect of the registration,
renewal or infringement of such trademarks and/or trade names or other emblems identical or similar to the corresponding signs
of Curetis in Distributor’s own or in any nominee’s name without the previous written consent of Curetis, and in the
event that any such registration is secured by Distributor, Distributor shall immediately upon request of Curetis make assignment
thereof or surrender the same, as Curetis may direct, or automatically within sixty (60) days after the termination of this Distribution
Agreement.

		21.	DURATION AND TERMINATION

		21.1	This Agreement shall have an initial term of three (3) years starting from the day of the first
product registration in any of the countries listed as Territory in Attachment 1.5 of this agreement. It shall be automatically
extended for additional terms of twelve (12) months each, provided that it is not terminated by one Party in writing with six months’
prior notice effective as of the end of the respective term.

		21.2	Curetis shall have the right to terminate the Agreement pursuant to Section 6.2 above in case that
Distributor fails to meet the Minimum Purchase.

		21.3	This Agreement may be terminated for cause upon written notice by either Party at any time during
the term of this Agreement if it is proven by reasonable evidence that the other Party is in breach of its essential obligations
hereunder by causes and

    	20 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.

    

reasons within its control, and
the said breaching Party has not cured such breach within thirty (30) days after notice requesting the correction of the breach.

		21.4	The following reasons shall in particular, but not limited to, be deemed causes justifying a termination
under this Section 21.3:

		(a)	Insolvency proceedings or a similar winding up of the business outside the insolvency law of Distributor’s
assets or the refusal of insolvency due to a lack of assets;

		(b)	Material adverse change in the financial conditions of the Distributor;

		(c)	Occurrence of a change of control of Distributor resulting in Distributor coming under direct or
indirect control of any person, undertaking or organization which was not in control of Distributor as of the date of execution
of this agreement; and

		(d)	Defaults in payments or failure to make outstanding payment despite Curetis setting an appropriate
grace period.

		21.5	Distributor shall have the right to request for termination with 12 months written notice at any
time during the term of this Agreement if it is proven by valid evidence that the markets in the Territory are not profitable despite
commercially reasonable efforts. Curetis shall not unreasonably withhold such request. During this notice period Distributor is
obliged to ensure continuous supply and support of existing customers at the time of termination.

		21.6	Termination shall be in writing.

		22.	EFFECT OF TERMINATION

		22.1	Curetis shall not incur any liability whatsoever to Distributor as a result of or in connection
with any termination of this Agreement pursuant to Section 21.2 to 21.3 above and shall not be required to pay any compensation,
reimbursement, and/or damages on account of the loss of goodwill, clientele or prospective profit on anticipated sales, nor on
account of expenditures, investments, leases, and/or commitments of any kind made by Distributor in the course of performance hereunder.

		22.2	After giving or receiving notice of termination, Curetis shall be under no further obligation to
supply Distributor with new Products, with the exception of orders, received and accepted by Curetis before the date of the receipt
of notice of termination. Further supply to Distributor during the notice period is at Curetis sole discretion and Curetis may,
at its option prescribe terms of payment other than the terms stated in Section 9 above.

		22.3	Upon the effective expiration or termination of this Agreement, Distributor shall assign and transfer
to Curetis (at Curetis cost and reimbursements of advanced or renewal fees) all regulatory marketing approvals obtained by Distributor
for the

    	21 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.

    

Products in the Territory as well
as all other approvals from the competent health, medical device and other relevant authorities for import and distribution of
the Products in the Territory, provided that such assignment and transfer is legally permissible under the applicable laws and
regulations.

		22.4	Upon the effective expiration or termination of this Agreement, the Parties’ rights shall
immediately terminate and neither Party shall exercise thereafter any of its rights set forth in the Agreement, unless otherwise
set forth herein. Sections which survive the expiration or termination of the Agreement shall include but not be limited to Sections
1.3, 2.1(h), 5, 8.7, 9, 10, 11.2, 15, 16, 18 to 20, 22 and 26 to 28 subject to the terms stipulated therein. Expiration or termination
of this Agreement shall not affect any of the Parties’ obligations which exist as of the date of termination, or of those
obligations of Parties which, by the context of this Agreement, are intended to survive its termination.

		22.5	All trade names, patents, registration rights, designs, drawings, formulae, demonstration Products,
technical, scientific and sales literature and handbooks as well as advertising and other promotional material shall remain the
property of Curetis. Upon the effective expiration or termination of this Agreement Distributor shall return all such items within
thirty (30) days of the expiration or termination date to Curetis, at the expense of Curetis.

		22.6	Effective upon the effective expiration or termination of the Agreement, Distributor shall cease
to use any and all logos, labels, designs, trade names or other intellectual property rights of Curetis. Distributor shall no longer,
for any purposes whatsoever, make use of Curetis’ name and trademarks and shall not be entitled anymore to hold any rights
hereto.

		22.7	Following the effective expiration or termination Curetis, or its nominee, shall purchase all new,
unsold, unused, and not defective Products in the possession of Distributor in their original packaging which are not subject of
any contract with/or sub-distributors at the net price actually paid by Distributor to Curetis, provided that Distributor has documented
evidence for the correct shipment and storage of such Products. The risk of transportation and any costs involved in connection
therewith shall be borne by Curetis. Such repurchasing obligation shall not apply (i) to the extent that the inventory is based
on miscalculations of Distributor or (ii) in case that Curetis rightfully terminated the Agreement for cause for breach of an essential
obligation under Section 21.3 above or (iii) Distributor terminated the agreement according to Section 21.5 above.

		23.	CUSTOMER DATA

Upon request of Curetis and only
if allowed by (and in compliance with) the local laws of the customers and the Distributor, Distributor shall be obliged to make
available to Curetis and Curetis shall be entitled to make use of any data the Distributor receives on customers of the Products
in the Territory including their names and addresses.

    	22 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.

    

		24.	NOTICES

All notices, requests, demands
and other communications under this Agreement shall be in English and in writing and shall be deemed to have been duly given if
delivered or if mailed by registered mail prepaid, or sent and received via fax to the Parties at the following addresses, or at
such other addresses as may be given in writing in the future by either Party to the other:

If to Curetis: CEO, cc Head of
Legal, cc Head of Sales

Curetis AG, Max-Eyth
Strasse 42, 71088 Holzgerlingen,

Germany

Name of Curetis’ designated
representative: Oliver Schacht, PhD

If to Distributor: CEO,

Acumen Research Laboratories Pte
Ltd

Diagnostics Development (DxD) Hub

10 Biopolis Road, #03-01, Singapore 138670.

Name of Distributor’s designated
representative: Siew Hwa Ong, PhD

		25.	ASSIGNMENT

		25.1	This Agreement and all rights and obligations hereunder are personal to Distributor and Distributor
shall not assign, transfer, delegate, sell, sublicense or otherwise dispose of this Agreement or any or all rights and obligations
under this Agreement without the prior written consent of Curetis, and any purported assignment, transfer, delegation, sale, sublicense
or other disposal hereof shall not be binding upon Curetis.

		25.2	Curetis may, at its sole discretion, assign this Agreement to any third party nominated by it.

		26.	RIGHT OF RETENTION AND SET-OFF

A Party may only offset counterclaims
if such counterclaims are with regard to their cause and amount undisputed, accepted or have been bindingly established in court.
The same shall apply in case of a right of retention.

		27.	GOVERNING LAW, DISPUTES

This Agreement shall be governed
by and interpreted in accordance with the laws of Germany excluding the provisions of conflicts of laws. The UN Convention on Contracts
for the International Sale of Goods is excluded.

    	23 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.

    

All disputes arising out of or
in connection with the present contract shall be finally settled under the Rules of Arbitration of the International Chamber of
Commerce by one or more arbitrators appointed in accordance with the said Rules. Place of arbitration shall be Zurich, Switzerland.

		28.	FINAL PROVISIONS

		28.1	The failure of either Party to demand execution of any of the terms of this Agreement, or the waiver
by either Party of any breach under this Agreement shall not prevent a subsequent enforcement of such terms, nor be deemed a waiver
of any subsequent breach.

		28.2	This Agreement, incorporating its attachments, as implemented by purchase orders for Products or
ingredients, is intended to be the entire agreement regarding of the Parties as to the sale and purchase of the Products, and supersedes
all previous understandings, negotiations and proposals. Purchase orders shall be entered into subject to and in accordance with
the provisions of this Agreement, and none of the provisions printed, typed or otherwise written thereon shall have any force or
effect or be otherwise applicable, except those setting forth the description of the sections and Prices applicable thereto, which
shall be in accordance with the provisions hereof.

		28.3	This Agreement may not be altered, amended or modified, except in writing, signed by duly authorized
representatives of the Parties hereto. The same applies in case of a waiver of this written form requirement.

		28.4	Should any part of this Agreement for any reason be invalid or unenforceable, such invalidity or
unenforceability shall not affect the validity of the remaining portion, which remaining portion shall continue in full force and
effect. In such case, the Parties agree that they will, in good faith, negotiate with one another to replace such invalid provision
with a valid provision, as similar as possible to that which has been held to be invalid.

		28.5	All Attachments to this Agreement form an inseparable part thereof.

		29.	CHANGE OF CONTROL

		29.1	“Change of Control” of any the Companies is defined as: (i) a merger or consolidation
of the Company in which the stockholders of the Company immediately prior to such transaction would own, in the aggregate, less
than 50% of the total combined voting power of all classes of capital stock of the surviving entity normally entitled to vote for
the election of directors of the surviving entity or (ii) the sale by the Company of all or substantially all the Company’s
assets in one transaction or in a series of related transactions or (iii) the liquidation of the company.

		29.2	A party is entitled to terminate this Agreement under any of the following change of control events
as described in 29.1 of the other party.

    	24 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.

    

		29.3	In the event of a change of control of Curetis, Distributor shall be entitled to sell off any inventory
of Curetis Products for six months following the date of notification of termination of this Agreement. As of the expiration of
the six months period, Distributor shall have the Products repurchased by Curetis at a then fair market value to be determined
in good faith between the parties, provided that the referred products are in good sale condition and shelf life is not less than
three months.

 

 

    	25 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.

    

 

This Agreement has been entered into
on the date stated at the beginning of this Agreement.

	
        Curetis A

        represented by:
	 	 
	
        /s/ Oliver Schacht

        Name: Oliver Schacht

        Title: CEO
	 	
        /s/ Achim Plum

        Name: Dr. Achim Plum

        Title: CCO

	
        Acumen Research Laboratories Pte Ltd

        represented by:
	 	 
	
        /s/ Siew Hwa Ong

        Name:
        Siew Hwa Ong, PhD

        Title: CEO
	 	
        /s/ Allan Lee (Li Yuanhan)

        Allan Lee (Li Yuanhan, MSC)

        Title: Research Associate

 
 

    	26 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.

    

 

ATTACHMENT 1.1 (A)

PRODUCTS

Curetis UnyveroTM Solution
consisting of:

1 UnyveroTM A50 Analyzer

1 UnyveroTM L4 Lysator

1 UnyveroTM C8 Cockpit

1 UnyveroTM P55 Pneumonia Set

Includes:

12 UnyveroTM P55 Pneumonia
Cartridges

12 UnyveroTM T1 Sample
Tubes, with lysis reagents

12 UnyveroTM T1 Sample
Tube Caps, includes quality control

12 UnyveroTM T1 Sample
Transfer Tools, special sample pipetting aid

1 UnyveroTM i60 ITI Set (subject
to availability after completed CE approval)

Includes:

12 UnyveroTM i60 ITI
Cartridges

12 UnyveroTM T1 Sample
Tubes, with lysis reagents

12 UnyveroTM T1 Sample
Tube Caps, includes quality control

12 UnyveroTM T1 Sample
Pretreatment Tool

12 UnyveroTM M1 Master Mix
Tubes

1 UnyveroTM Sample Tube holder

    	27 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.

    

 

ATTACHMENT 1.1 (B)

TERRITORY

Singapore, Indonesia, Malaysia and Thailand

 

 

    	28 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.

    

 

ATTACHMENT 1.5

Direct sales customers

[***]

 

    	29 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.

    

 

ATTACHMENT 3.6

TRADEMARKS, LOGOS AND OTHER MARKINGS

CURETIS AND UNYVERO IS A TRADEMARK
OF CURETIS AG

 

 

    	30 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.

    

 

ATTACHMENT 6.2

MINIMUM PURCHASE

[***]

 

    	31 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.

    

 

ATTACHMENT 7.1

PRICES

[***]

 

 

    	32 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.

    

 

ATTACHMENT 2

DISTRIBUTION PRICES

To be agreed upon

 

 

    	33 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.

    

 

ATTACHMENT 8.1

STANDARD TERMS OF DELIVERY AND SALE

Standard Terms of Delivery and Sale of
Curetis AG

§1.General

The following Standard Terms of
Delivery and Sale shall apply to all offers, commissions, orders, deliveries and services relating to the delivery and sale of
our products; as well as any other agreements, offers, commissions, orders, deliveries and services concluded within the scope
of existing business relations in the future, even if these terms have not been agreed explicitly. Any deviations here from must
be agreed in writing. Other, deviating terms (in particular other Standard Terms and Conditions) shall not be part of the agreement,
unless we have expressly and in written form consented to their applicability. This shall apply even if we have not explicitly
opposed these terms or if there is no corresponding (specific or general) provision to this effect in our Standard Terms of Delivery
and Sale. In this case, statutory law shall apply. Curetis reserves the right to change its Standard Terms of Delivery and Sale
at any time.

§2.Offers, scope of performance,
written form

		1.	We may accept an order made pursuant to § 145 German Civil Code (BGB) within
two weeks by sending a written confirmation.

		2.	The scope of our services is subsequently determined by our written confirmation of order in connections
with these Standard Terms of Delivery and Sale.

		3.	Supplementary agreements and/or amendments shall only come into effect once they have been confirmed
by us in writing. Written form may neither be replaced by simple nor qualified electronic form.

§3.Prices

		1.	Our prices are to be understood as EXW (Incoterms 2010) from our distribution warehouses
plus packaging, loading and sales tax in the respective statutory amount. Services shall be charged in Euro according
to the prices valid on the date of delivery plus the applicable statutory Value Added Tax. We will state the statutory amount
of the sales tax applicable on the billing date separately in the invoice.

		2.	In the event of an increase in costs for which we are not responsible, we reserve the right
to increase the prices accordingly.

§4.Delivery period, terms of
delivery

		1.	Our products and consumables will be delivered as quickly as possible after confirmation of order.

		2.	The adherence to a delivery period agreed upon in writing shall require the prior clarification
of all commercial and technical issues between us and the buyer and the buyer’s fulfillment of all obligations incumbent
upon him. Should this not be the case, the delivery time shall be extended by a reasonable period of time.
We reserve the right to further rights and claims.

		3.	Part deliveries by us shall be permissible, unless this is considered to be unreasonable
for the other contracting party.

 

    	34 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.

    

		4.	In the event of delayed delivery caused by force majeure and impediments which are beyond our control
and responsibility (including the fault of our suppliers, stoppages, labor disputes, etc.) the
contracting party shall not be entitled to claim compensation for damages.

		5.	Goods shall always be dispatched by Curetis at the buyer’s own risk.

§5.Payments, right to off-set

		1.	Unless stated to the contrary, all payments shall become due within 14 days of the billing
date. All payments are to be made in full by wire transfer to one of our accounts without deductions.

		2.	In the event of default, we shall be entitled to charge default interest at a rate of 5
percent (in the case of traders 9 percent) points above the base lending rate. Furthermore, we shall
be entitled to additional compensation by law.

		3.	A contracting party may only offset (aufrechnen) counterclaims if such counterclaims
are with regard to their cause and amount undisputed, accepted or have been bindingly established in court. The same
shall apply in case of a right of retention (Zuruckbehaltungsrecht).

§6.Retention of title

Delivered goods shall remain our
property until all outstanding payments from the buyer have been received. This also applies for future and contingent claims.
For open accounts the reserved goods are deemed to be security for our claims. The buyer shall not be entitled to pledge or assign
our reserved goods as security to third parties.

§7.Inspection and objection

The buyer agrees to duly inspect
the delivered goods immediately upon delivery at his own account and to report to us without delay any defects, wrong deliveries
or short deliveries in writing. Notice of obvious defects, wrong deliveries or short deliveries must be issued within a period
of 2 weeks following delivery. Unless set forth otherwise in this § 7, § 377 German Commercial Code (HGB) shall apply.

§8. Warranty, statute of limitations

Any claims for damages or reimbursement
of frustrated expenses are subject to the following restrictions regardless of their legal basis:

		1.	We shall be fully liable in the event of intentional misconduct (Vorsatz) or gross negligence (grobe
Fahrlassigkeit) by Curetis AG, our legal representatives or vicarious agents (Erfullungsgehilfen). In addition, we shall be fully
liable (i) in the case of non-compliance with guarantees (Garantien), (ii) in the case of culpable injury to life, body and health
caused by Curetis AG, our legal representatives or vicarious agents and (iii) in case of a statutory liability under the German
Product Liability Act (Produkthaftungsgesetz).

		2.	In the case of a culpable violation of essential contractual obligations, meaning principal
obligations enabling the proper execution of the contract and upon which the buyer therefore relies and may rely, we shall
be liable on the merits. The liability shall in this case, however, be limited to the contractually typical
damage that can be reasonably foreseen.

 

    	35 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.

    

		3.	In all other cases, any claims for direct or indirect damages (on any legal basis
whatsoever) including any compensation claims based on breach of any pre-contractual duty, or tortuous claims shall
be excluded.

		4.	Claims for product defects shall become time-barred twenty-four (24) months after buyer received
the instrument systems, and shall become time-barred, in case of properly stored consumables, within the consumables’ expiration
period or within three (3) months after buyer received said consumables, whichever comes earlier. This limitation shall not apply
in case of a liability of Curetis AG due to intentional misconduct (Vorsatz) or gross negligence (grobe Fahr-lassigkeit) by Curetis
AG, our legal representatives or vicarious agents (Erful-lungsgehilfen) and in the case of culpable injury to life, body
and health by us, our legal representatives or vicarious agents.

§9.Authorized Use

		1.	Our products are intended only for the uses stated in our respective product documentations.
Any other type of consumption or application in humans or animals is not permissible.

		2.	It is understood that should you, as the purchaser of our products, decide to exceed
the above-mentioned limitations of our products in any way, you are completely responsible for obtaining any necessary intellectual
property permission, compliance with any and all applicable regulatory requirements and conducting necessary testing.

§10.Data protection

Prior to publishing any data generated
by us in the course of a collaboration - in the event of our company name being named - our prior written approval shall be sought.

§11.Cancellation, return

The return of faultless goods
shall require our prior written approval. In the event of the order being cancelled unilaterally by the buyer, he shall bear all
costs incurred as a result of the cancellation and/or return of the goods. Further rights exist pursuant to § 649 German Civil
Code (BGB) and shall not be excluded herewith.

§12.Place of performance, choice
of law, jurisdiction

		1.	The place of performance and fulfillment for obligations of the buyer shall be our principal place
of business in Holzgerlingen, Germany.

		2.	This contract is governed by the law of the Federal Republic of Germany to the exclusion of all
other conflicting laws and the UN convention on Contracts for the International Sale of Goods (CISG).

		3.	For traders, corporate bodies under public law as well as separate estate under public law
as well as all cases referring to transactions abroad, the following applies: All disputes arising here from shall be settled
before a competent court of law in Stuttgart, Germany. In addition, we are entitled to bring actions to the
court of the customer’s residence.

§13.Severability

If a provision in this Agreement
should be or become invalid, this shall not affect the validity of the remaining provisions. The parties shall replace the invalid
provision by a valid provision which comes as close as possible to the sense and purpose of the invalid provision. The above applies
accordingly in case of gaps.

 

    	36 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.

    

ATTACHMENT 11.1

STORAGE CONDITIONS

	
        UNYVEROTM

        L4 LYSATORS
	18°C to 35 °C
	
        UNYVEROTM

        C8 COCKPITS
	18°C to 35 °C
	
        UNYVEROTM

        A50 ANALYZERS
	18°C to 35 °C
	
        UNYVEROTM

        P55 PNEUMONIA SETS (EXCL. M I MASTER
        MIX)
	15°C to 25° C
	
        UNYVEROTM

        i60 ITI SETS (EXCL. M1 MASTER MIX)
	15°C to 25° C
	UNYVEROTM M1 MASTER MIX	-20°C longterm (> 7d), up to +4° C short term (< 7d)

 

Or as otherwise described in the then
current version of the applicable Instructions for Use of the respective Product as provided in writing by Curetis to Distributor.
In case of ambiguity, the last version of the applicable Instructions for Use of the respective Product provided in writing by
Curetis to Distributor shall prevail.

 

    	37 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.Exhibit
10.34.2

 

Certain identified information
has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly
disclosed. [***] indicates that information has been redacted.

 

Amendment 1

to the Exclusive International Distribution
Agreement (“EIDA”)

dated October 5, 2015

entered into as of November 15, 2017 (“Effective
Date”)

by and between

Curetis GmbH and Acumen Research Laboratories
Pte Ltd (collectively the Parties)

The Parties agree to amend the aforementioned
EIDA as follows:

		·	Distributor agrees to distribute the Unyvero BCU application in the Territory and such cartridges
to become part of the Products list of the EIDA. The enclosed updated Attachment 1.1 (A) “Products” shall supersede
the original Attachment 1.1(A).

		·	Distributor agrees to participate in BCU application training combined with a software training.

		·	Distributor will ensure a timely update of any marketing materials affected by the product release
of the Unyvero BCU cartridge and new software. Curetis shall support this effort and shall provide distributor with samples of
advertising and other promotional material in the English language free of charge.

		·	Curetis will make available to Distributor the relevant Unyvero software free of charge upon completion
of the aforementioned training and fulfilment of any regulatory prerequisites in Territory.

		·	Distributor shall install the software upgrade and provide necessary customer training to any customer
prior to providing Unyvero BCU cartridges.

		·	Distributor will include the Unyvero BCU cartridge forecasting in the next regular forecast following
the Effective Date of this amendment.

		·	Enclosed Attachment 7.1 “Prices” shows the current Curetis distributor transfer price
list (as of January 1, 2017), including the transfer pricing for the Unyvero BCU blood culture application and shall supersede
the original Attachment 7.1.

		·	Enclosed Attachment 11.1 “Storage Conditions” shall supersede the original Attachment
11.1.

		·	The following shall become part of the EIDA as section 2.1 (p): “Distributor shall inform
Curetis about the intention of a customer in the territory to set up a trial/study with the

 

    	 

    	 

    

 

Certain identified information has been excluded from this
exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates
that information has been redacted.

 

 

Unyvero system. Curetis shall use
its best efforts to support the customer in issues related to such trial/study. Distributor is obliged, should one of his customers
intend to publish data arisen from such a trial/study, to make available to Curetis in compliance with applicable patient data
protection laws, rules and regulations, the data as well as manuscripts based on these data thirty (30) days prior to submission
for publication for review, comment and approval. Customer will consider Curetis’ comments for integration into the manuscripts
provided that they are factually correct and do not compromise the scientific quality and integrity of the publication. Curetis
agrees not to deny approval without serious cause.”.

		·	The original Section 28 “final provisions” of the EIDA now becomes Section 30 and a
new Section 28 “Compliance” shall be inserted:

“COMPLIANCE

		28.1	In 2015 Curetis Code of Conduct was first passed and put into practice. It sets forth our standards
to promote honest and ethical conduct with all of Curetis’ stakeholders, including its Distributors. It is binding for all
employees of Curetis worldwide and covers among others conflicts of interest, gifts or entertainment, protecting privacy and confidentiality
as well as fraud, dishonesty or criminal conduct. Our Code is supplemented by further policies on specific areas and is part of
Curetis’ constant endeavor to ensure its commitment to lawful and ethical behavior. Therefore, and to take along the Distributor
in this endeavor, Distributor agrees to observe the regulations of Curetis Code of Conduct, which can easily be found on Curetis
homepage.

		28.2	The Distributor is aware that he might be dealing with (foreign) officials that are subject to
anti-bribery and anti-corruption laws while performing his services. Accordingly, the Distributor hereby represents and warrants
that:

		(a)	Distributor is in compliance with the applicable laws, especially any anti-bribery and anti-corruption
laws and will remain in compliance with all such at least for the duration of the Agreement.

		(b)	Distributor has not taken and will not take any actions in furtherance of an offer, payment, promise
to pay, or authorization of the payment or giving of money, or anything else of value, to any government official (including any
officer or employee of any government or government-controlled entity or of a public international organization, or any person
acting in an official or representative capacity for or on behalf of any of the foregoing, or any political party or official thereof,
or candidate for political office, or legislative, administrative or judicial officials whether or not elected or appointed, all
of the foregoing being referred to as “Government Officials”) or to any other person while knowing that all or some
portion of the money or value will be offered, given or promised to a Government Official for the purposes of obtaining or retaining
business, an advantage in the conduct of business, securing any improper advantage or improper performance of that person’s
function or misuse of its position.

		28.3	In connection with the foregoing representations and warranties of Section 28.2, the Parties further
agree as follows:

 

    	2 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
 
 

    

		(a)	When a situation arises indicating a possible breach of the foregoing representations and warranties
of this article by the Distributor, the Distributor permits CURETIS to conduct an audit of its records and books of account related
to this Agreement only, during normal business hours. The Distributor supports the audit to the best of its abilities, especially
in granting free access to a room on its business premises for the audit to take place there and in supplying all details, reports,
data and other information relating to this Agreement as CURETIS may reasonably request.

		(b)	In the event of a breach the Distributor shall indemnify and hold harmless the Principal against
any and all claims, losses or damages arising from or related to such breach or cancellation of this contract.”

		·	A new Section 21.5 shall be inserted into the EIDA: “In addition, this Agreement may be terminated
by CURETIS with immediate effect, if the Distributor is in breach of Section 28 (Compliance).”

All other clauses of the EIDA shall
remain unchanged and in full force and effect.

	
        Curetis GmbH

        represented by:

         

         

        /s/ Achim Plum
	 	
        Acum Research Labortories Pte Ltd

        represented by:

         

         

        /s/ Siew Hwa Ong

	 
	
        Name: Dr. Achim Plum

        Title: Managing Director

        Date: 22 Nov 2017

         

         

        /s/ Oliver Schacht
	 	
        Name: Siew Hwa Ong, PhD

        Title: Managing Director

        Date: 15 Nov 2017

         

         

        /s/ Li Ywanhan

	 
	Name: Oliver Schacht, Ph.D.

Title: Managing Director

Date: 22 Nov 2012	 	Name: Li Ywanhan

Title: Research Associate

Date: 15 Nov 2017

 

Enclosure: new attachments 1.1 (A) –
Products; 7.1– Prices; 11.1 - Storage Conditions

    	3 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
 
 

    

 

ATTACHMENT 1.1(A)

PRODUCTS

I.       Curetis
Unyvero Solution consisting of:

		·	1x Unyvero A50 Analyzer (Article-No.: 60001)

		·	lx Unyvero L4 Lysator (Article-No.: 60002)

Includes:
1 Unyvero Sample Tube holder

		·	lx Unyvero C8 Cockpit (Article-No.: 60003)

II.       1
Unyvero P55/HPN Cartridge Set (Article-No.: 10047) Includes:

		·	12x Unyvero P55/HPN Pneumonia Cartridge

		·	12x Unyvero T1 Sample Tube (Article-No.: 10012), with lysis reagents

		·	12x Unyvero T1 Sample Tube Cap (Article-No.: 10013), includes quality control

		·	12x Unyvero Tl Sample Transfer Tool (Article-No.: 10014), special sample pipetting aid

III.       1
Unyvero i60/ITI Cartridge Set (Article-No.: 10041) Includes:

		·	12x Unyvero ITI Cartridge

		·	12x Unyvero T1 Sample Tube (Article-No.: 10012), with lysis reagents

		·	12x Unyvero T1 Sample Tube Cap (Article-No.: 10013), includes quality control

		·	12x Unyvero T1 Sample Pretreatment Tool (Article-No.: 10043)

IV       1
Unyvero BCU Cartridge Set (Article-No.: 10051) Includes:

		·	12x Unyvero BCU Cartridge

		·	12x Unyvero B1 Sample Tube (Article-No.: 10063), with lysis reagent

		·	12x Unyvero B1 Sample Tube Cap (Article-No.: 10062), includes quality control

    	4 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
 
 

    

		·	12x Unyvero B1 Collection Tube (Article-No.: 10061), handling tool to pipette required sample volume

V.       1
Unyvero M1 Master Mix Tube (Article-No.: 10011) Includes:

		·	12x Unyvero M1 Master Mix Tube (10002)

 
 

    	5 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
 
 

    

 

ATTACHMENT 7.1

TRANSFER PRICES

[***]

 

    	6 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
 
 

    

 

ATTACHMENT 11.1

STORAGE CONDITIONS

	
        Unyvero

        L4 Lysators
	18 °C to 35 °C
	
        Unyvero

        C8 Cockpits
	18°C to 35°C
	
        Unyvero

        A50 Analyzers
	18°C to 35°C
	
        Unyvero

        P55/HPN Hospitalised
        Pneumonia Sets (excl. M1 Master Mix)
	15°C to 25°C
	
        Unyvero

        i60/ITI Sets (excl.
        M1 Master Mix)
	15°C to 25°C
	
        Unyvero

        BCU Sets (excl. M1
        Master Mix
	15°C to 25°C
	
        UnyveroTM M1
        Master Mix

         
	-20°C long term (> 7d), up to +4 °C short term (<7d)

 

Or as otherwise described in the then
current version of the applicable Instructions for Use of the respective Product as provided in writing by Curetis to Distributor.
In case of ambiguity, the last version of the applicable Instructions for Use of the respective writing by Curetis to Distributor
shall prevail.

 

    	7 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00302-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00302-of-00352.parquet"}]]